

Print a copy and give it to
your eye care professional



YUVEZZI is the only dual-agent eye drop for presbyopia that combines two active ingredients for consistent miosis¹



Only one drop,
once a day¹



Up to 8-hour duration
of functional near-vision
improvement^{1*}

- About half of people in medical studies could read close up at hour 8¹



Proven tolerability for daily
and long-term use^{1,2}

- 12-month safety profile with no observed retinal detachments²
- Less hyperemia than with carbachol alone²

Individuals with pre-existing retinal disease are at increased risk of retinal detachment. Examination of the retina is advised in all patients prior to the initiation of therapy.¹



Eye doctors can scan for sample requests,
pricing, and prescribing information.

***Study Design:** The efficacy of YUVEZZI was evaluated in 618 patients (aged 45 to 80) with presbyopia in two Phase 3 randomized, double-masked, controlled studies. The primary endpoint was the proportion of participants achieving a gain from baseline of 3 lines (15 letters) or more in binocular uncorrected near visual acuity (BUCNVA) without a loss of 1 line (5 letters) or more in binocular uncorrected distance visual acuity (BUCDVA) under mesopic conditions. The proportions were significantly higher following YUVEZZI than following vehicle, brimonidine alone, or carbachol alone.¹

Indication

YUVEZZI is indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

YUVEZZI is not recommended to be used when iritis is present.

Avoid touching the vial to the eye, eyelids, or to any other surface.

YUVEZZI may potentiate syndromes associated with vascular insufficiency.

Drug Interactions

- Antihypertensives/cardiac glycosides, tricyclic antidepressants, and monoamine oxidase inhibitors: caution advised.
- CNS depressants: consider the possibility of additive or potentiating effects.

Adverse Reactions

The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional safety information, see the full Prescribing Information at YUVEZZIlecp.com.

References: 1. YUVEZZI Prescribing Information. Visus Therapeutics, Inc.; 2026. 2. Visus Therapeutics, Inc. Data on file. VT-003 Clinical Study Report. 2025.



© 2026 Tenpoint Therapeutics, Ltd. ALL RIGHTS RESERVED
YUVEZZI is a trademark of Visus Therapeutics, Inc. TENPOINT is a trademark of Tenpoint Therapeutics Holding Limited.
Visus Therapeutics, Inc., is an affiliate of Tenpoint Therapeutics, Ltd., Warren, NJ 07059 USA.
MAT-US-YZ-0399 07/26